Literature DB >> 19058137

Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.

Claudia A Salinas1, Joseph S Koopmeiners, Erika M Kwon, Liesel FitzGerald, Daniel W Lin, Elaine A Ostrander, Ziding Feng, Janet L Stanford.   

Abstract

BACKGROUND: A recent report suggests that the combination of five single-nucleotide polymorphisms (SNPs) at 8q24, 17q12, 17q24.3 and a family history of the disease may predict risk of prostate cancer. The present study tests the performance of these factors in prediction models for prostate cancer risk and prostate cancer-specific mortality.
METHODS: SNPs were genotyped in population-based samples from Caucasians in King County, Washington. Incident cases (n = 1,308), aged 35-74, were compared to age-matched controls (n = 1,266) using logistic regression to estimate odds ratios (OR) associated with genotypes and family history. Cox proportional hazards models estimated hazard ratios for prostate cancer-specific mortality according to genotypes.
RESULTS: The combination of SNP genotypes and family history was significantly associated with prostate cancer risk (p(trend) = 1.5 x 10(-20)). Men with > or =5 risk factors had an OR of 4.9 (95% CI 1.6-18.5) compared to men with none. However, this combination of factors did not improve the ROC curve after accounting for known risk predictors (i.e., age, serum PSA, family history). Neither the individual nor combined risk factors was associated with prostate cancer-specific mortality.
CONCLUSION: Genotypes for five SNPs plus family history are associated with a significant elevation in risk for prostate cancer and may explain up to 45% of prostate cancer in our population. However, they do not improve prediction models for assessing who is at risk of getting or dying from the disease, once known risk or prognostic factors are taken into account. Thus, this SNP panel may have limited clinical utility. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19058137      PMCID: PMC2788301          DOI: 10.1002/pros.20887

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  25 in total

1.  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men.

Authors:  Matthew L Freedman; Christopher A Haiman; Nick Patterson; Gavin J McDonald; Arti Tandon; Alicja Waliszewska; Kathryn Penney; Robert G Steen; Kristin Ardlie; Esther M John; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

2.  Multiple regions within 8q24 independently affect risk for prostate cancer.

Authors:  Christopher A Haiman; Nick Patterson; Matthew L Freedman; Simon R Myers; Malcolm C Pike; Alicja Waliszewska; Julie Neubauer; Arti Tandon; Christine Schirmer; Gavin J McDonald; Steven C Greenway; Daniel O Stram; Loic Le Marchand; Laurence N Kolonel; Melissa Frasco; David Wong; Loreall C Pooler; Kristin Ardlie; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Esther M John; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich
Journal:  Nat Genet       Date:  2007-04-01       Impact factor: 38.330

3.  Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.

Authors:  Liang Wang; Shannon K McDonnell; Joshua P Slusser; Scott J Hebbring; Julie M Cunningham; Steven J Jacobsen; James R Cerhan; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

4.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.

Authors:  Julius Gudmundsson; Patrick Sulem; Valgerdur Steinthorsdottir; Jon T Bergthorsson; Gudmar Thorleifsson; Andrei Manolescu; Thorunn Rafnar; Daniel Gudbjartsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Thorarinn Blondal; Simon N Stacey; Agnar Helgason; Steinunn Gunnarsdottir; Adalheidur Olafsdottir; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Steinunn Thorlacius; Dana Magnusdottir; Gerdur Stefansdottir; Kristleifur Kristjansson; Yu Bagger; Robert L Wilensky; Muredach P Reilly; Andrew D Morris; Charlotte H Kimber; Adebowale Adeyemo; Yuanxiu Chen; Jie Zhou; Wing-Yee So; Peter C Y Tong; Maggie C Y Ng; Torben Hansen; Gitte Andersen; Knut Borch-Johnsen; Torben Jorgensen; Alejandro Tres; Fernando Fuertes; Manuel Ruiz-Echarri; Laura Asin; Berta Saez; Erica van Boven; Siem Klaver; Dorine W Swinkels; Katja K Aben; Theresa Graif; John Cashy; Brian K Suarez; Onco van Vierssen Trip; Michael L Frigge; Carole Ober; Marten H Hofker; Cisca Wijmenga; Claus Christiansen; Daniel J Rader; Colin N A Palmer; Charles Rotimi; Juliana C N Chan; Oluf Pedersen; Gunnar Sigurdsson; Rafn Benediktsson; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; William J Catalona; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

5.  A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix.

Authors:  J CORNFIELD
Journal:  J Natl Cancer Inst       Date:  1951-06       Impact factor: 13.506

6.  Clinically useful measures of effect in binary analyses of randomized trials.

Authors:  J C Sinclair; M B Bracken
Journal:  J Clin Epidemiol       Date:  1994-08       Impact factor: 6.437

7.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

Authors:  Julius Gudmundsson; Patrick Sulem; Andrei Manolescu; Laufey T Amundadottir; Daniel Gudbjartsson; Agnar Helgason; Thorunn Rafnar; Jon T Bergthorsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Jianfeng Xu; Thorarinn Blondal; Jelena Kostic; Jielin Sun; Shyamali Ghosh; Simon N Stacey; Magali Mouy; Jona Saemundsdottir; Valgerdur M Backman; Kristleifur Kristjansson; Alejandro Tres; Alan W Partin; Marjo T Albers-Akkers; Javier Godino-Ivan Marcos; Patrick C Walsh; Dorine W Swinkels; Sebastian Navarrete; Sarah D Isaacs; Katja K Aben; Theresa Graif; John Cashy; Manuel Ruiz-Echarri; Kathleen E Wiley; Brian K Suarez; J Alfred Witjes; Mike Frigge; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; Lambertus A Kiemeney; William B Isaacs; William J Catalona; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-04-01       Impact factor: 38.330

8.  A common 8q24 variant in prostate and breast cancer from a large nested case-control study.

Authors:  Fredrick R Schumacher; Heather Spencer Feigelson; David G Cox; Christopher A Haiman; Demetrius Albanes; Julie Buring; Eugenia E Calle; Stephen J Chanock; Graham A Colditz; W Ryan Diver; Alison M Dunning; Matthew L Freedman; John M Gaziano; Edward Giovannucci; Sue E Hankinson; Richard B Hayes; Brian E Henderson; Robert N Hoover; Rudolf Kaaks; Timothy Key; Laurence N Kolonel; Peter Kraft; Loic Le Marchand; Jing Ma; Malcolm C Pike; Elio Riboli; Meir J Stampfer; Daniel O Stram; Gilles Thomas; Michael J Thun; Ruth Travis; Jarmo Virtamo; Gerald Andriole; Edward Gelmann; Walter C Willett; David J Hunter
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

9.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.

Authors:  Meredith Yeager; Nick Orr; Richard B Hayes; Kevin B Jacobs; Peter Kraft; Sholom Wacholder; Mark J Minichiello; Paul Fearnhead; Kai Yu; Nilanjan Chatterjee; Zhaoming Wang; Robert Welch; Brian J Staats; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Geraldine Cancel-Tassin; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; Edward P Gelmann; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; David J Hunter; Stephen J Chanock; Gilles Thomas
Journal:  Nat Genet       Date:  2007-04-01       Impact factor: 38.330

10.  Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus.

Authors:  Christiane Robbins; Jada Benn Torres; Stanley Hooker; Carolina Bonilla; Wenndy Hernandez; Angela Candreva; Chiledum Ahaghotu; Rick Kittles; John Carpten
Journal:  Genome Res       Date:  2007-10-31       Impact factor: 9.043

View more
  52 in total

1.  Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.

Authors:  Aubrey R Turner; Brian R Lane; Dan Rogers; Isaac Lipkus; Kathryn Weaver; Suzanne C Danhauer; Zheng Zhang; Fang-Chi Hsu; Sabrina L Noyes; Tamara Adams; Helga Toriello; Thomas Monroe; Trudy McKanna; Tracey Young; Ryan Rodarmer; Richard J Kahnoski; Mouafak Tourojman; A Karim Kader; S Lilly Zheng; William Baer; Jianfeng Xu
Journal:  Cancer       Date:  2016-07-19       Impact factor: 6.860

Review 2.  The use of genomic information to optimize cancer chemotherapy.

Authors:  Federico Innocenti; Nancy J Cox; M Eileen Dolan
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

Review 3.  Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

Authors:  C R Balistreri; G Candore; D Lio; G Carruba
Journal:  Cancer Gene Ther       Date:  2014-01-10       Impact factor: 5.987

4.  Translating genomics into improved population screening: hype or hope?

Authors:  Nora Pashayan; Paul Pharoah
Journal:  Hum Genet       Date:  2011-04-12       Impact factor: 4.132

5.  Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy.

Authors:  Florian R Schroeck; Kimberly A Zuhlke; Javed Siddiqui; Rabia Siddiqui; Kathleen A Cooney; John T Wei
Journal:  J Urol       Date:  2012-10-02       Impact factor: 7.450

Review 6.  Prostate cancer in young men: an important clinical entity.

Authors:  Claudia A Salinas; Alex Tsodikov; Miriam Ishak-Howard; Kathleen A Cooney
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

7.  Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.

Authors:  Eric J Whitman; Mark Pomerantz; Yongmei Chen; Michael M Chamberlin; Bungo Furusato; Chunling Gao; Amina Ali; Lakshmi Ravindranath; Albert Dobi; Isabell A Sesterhenn; Isabell A Sestrehenn; David G McLeod; Shiv Srivastava; Matthew Freedman; Gyorgy Petrovics
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

8.  Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.

Authors:  Haitao Chen; Xu Liu; Charles B Brendler; Donna P Ankerst; Robin J Leach; Phyllis J Goodman; M Scott Lucia; Catherine M Tangen; Li Wang; Fang-Chi Hsu; Jielin Sun; A Karim Kader; William B Isaacs; Brian T Helfand; S Lilly Zheng; Ian M Thompson; Elizabeth A Platz; Jianfeng Xu
Journal:  Prostate       Date:  2016-05-16       Impact factor: 4.104

9.  Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.

Authors:  Wendy J Langeberg; Erika M Kwon; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

10.  Polygenic susceptibility to prostate and breast cancer: implications for personalised screening.

Authors:  N Pashayan; S W Duffy; S Chowdhury; T Dent; H Burton; D E Neal; D F Easton; R Eeles; P Pharoah
Journal:  Br J Cancer       Date:  2011-04-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.